Rare diseases
Investigational molecules
Locations
Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery
BelgiumStudy on Preoperative Treatment for HER2-Negative Breast Cancer Using Pembrolizumab, Paclitaxel, and Carboplatin in Patients Not Responding to Initial Chemotherapy
PolandStudy on Immune Markers for Checkpoint Inhibitor Toxicity in Cancer Patients Using Atezolizumab, Dexamethasone Sodium Phosphate, and Alizapride
BelgiumStudy on the Safety and Effectiveness of VB10.16 and Pembrolizumab for Patients with HPV16-Positive Head and Neck Cancer
CzechiaStudy of Tebentafusp and Pembrolizumab for Patients with Previously Treated Advanced Melanoma
AustriaStudy on Short vs. Long Immunotherapy with Pembrolizumab and Nivolumab for Patients with High-Risk Skin Melanoma After Surgery
FinlandStudy of Pembrolizumab and Cabozantinib for Patients with Advanced Sarcomas: Undifferentiated Pleomorphic Sarcoma, Osteosarcoma, and Ewing Sarcoma
FranceStudy of petosemtamab alone or with drug combination for patients with advanced colorectal cancer and other solid tumors
BelgiumStudy of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy
BelgiumStudy of Pembrolizumab for Patients with Classic or Endemic Kaposi's Sarcoma
FranceStudy on Maintenance Treatment with Pembrolizumab and Pemetrexed for Stage IV Non-Small Cell Lung Cancer Patients After Initial Chemotherapy and Immunotherapy
FranceStudy of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
